Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 6/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | IGF1R | P08069 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7127426 | 0.86 | RIPK2 (0.44) | RIPK2LMNAHPGDHTTEGFR | |
| SCHEMBL7126117 | 0.84 | RIPK2 (0.41) | RIPK2LMNAEGFRMKNK1PIK3CD | |
| SCHEMBL7119176 | 0.81 | RIPK2 (0.39) | RIPK2LMNAHPGDHTTEGFR | |
| SCHEMBL7125172 | 0.80 | EGFR (0.39) | RIPK2LMNAHPGDEGFRMKNK1 | |
| SCHEMBL7120220 | 0.76 | EGFR (0.41) | RIPK2EGFRTTK | |
| SCHEMBL7118837 | 0.73 | DYRK1A (0.38) | RIPK2EGFRMKNK1TTKIGF1R | |
| SCHEMBL7115986 | 0.73 | DYRK1A (0.38) | RIPK2HPGDMKNK1TTK | |
| SCHEMBL7129801 | 0.70 | RIPK2 (0.48) | RIPK2LMNAHPGDHTTEGFR | |
| SCHEMBL7125990 | 0.69 | CYP1A2 (0.36) | RIPK2MKNK1TTK | |
| SCHEMBL7118472 | 0.68 | EGFR (0.55) | RIPK2LMNAHTTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| WO-2001087845-A2 | N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176454-A1 | N-coating heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 | RIPK2 3457/4885LMNA 1315/4885HPGD 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.